Literature DB >> 15870017

Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor.

E E Perez1, J L Riley, R G Carroll, D von Laer, C H June.   

Abstract

Peptidomimetics of HIV-1 gp41 sequences required for membrane fusion are potent inhibitors of HIV-1 entry. We hypothesize that expression of a membrane-bound gp41-derived fusion inhibitor will confer HIV-1 resistance to primary CD4 T cells. Efficient gene delivery and stable expression of a membrane-bound gp41-derived fusion inhibitor to primary CD4 T cells was accomplished using a self-inactivating lentiviral vector. A potent antiviral effect was observed when transduced CD4 T cells were challenged with a highly virulent CXCR4-tropic strain of HIV-1. Production of soluble p24 in the supernatant was inhibited 100-fold, and cytopathic effects were evident early in non-transduced cells and absent in transduced cells. Expression of the gp41 sequences was not detrimental to CD4 cells as transduced CD4 T cells exhibited a population doubling time that was equivalent to T cells transduced with a control vector. Results from this study support the rationale to use this lentiviral vector targeted at HIV entry as a potential gene therapy for HIV infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870017     DOI: 10.1016/j.clim.2005.02.019

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  19 in total

1.  A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.

Authors:  Katarzyna Urbanska; Evripidis Lanitis; Mathilde Poussin; Rachel C Lynn; Brian P Gavin; Sander Kelderman; Jason Yu; Nathalie Scholler; Daniel J Powell
Journal:  Cancer Res       Date:  2012-02-07       Impact factor: 12.701

2.  A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Xiaoran Tang; Hongliang Jin; Yue Chen; Li Li; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

Review 3.  Novel cell and gene therapies for HIV.

Authors:  James A Hoxie; Carl H June
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

Review 4.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

5.  Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.

Authors:  Chaobaihui Ye; Weiming Wang; Liang Cheng; Guangming Li; Michael Wen; Qi Wang; Qing Zhang; Dan Li; Paul Zhou; Lishan Su
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

Review 6.  Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.

Authors:  James L Riley; Luis J Montaner
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

7.  Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells.

Authors:  Amal Kambal; Gaela Mitchell; Whitney Cary; William Gruenloh; Yunjoon Jung; Stefanos Kalomoiris; Catherine Nacey; Jeannine McGee; Matt Lindsey; Brian Fury; Gerhard Bauer; Jan A Nolta; Joseph S Anderson
Journal:  Mol Ther       Date:  2010-11-30       Impact factor: 11.454

8.  Establishing a dual knock-out cell line by lentivirus based combined CRISPR/Cas9 and Loxp/Cre system.

Authors:  Ya Li; Weifeng Zhang; Junli Zhao; Sai Li; Linlin Shan; Jiuling Zhu; Yan Li; He Zhu; Qinwen Mao; Haibin Xia
Journal:  Cytotechnology       Date:  2018-09-01       Impact factor: 2.058

9.  RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

Authors:  David L DiGiusto; Amrita Krishnan; Lijing Li; Haitang Li; Shirley Li; Anitha Rao; Shu Mi; Priscilla Yam; Sherri Stinson; Michael Kalos; Joseph Alvarnas; Simon F Lacey; Jiing-Kuan Yee; Mingjie Li; Larry Couture; David Hsu; Stephen J Forman; John J Rossi; John A Zaia
Journal:  Sci Transl Med       Date:  2010-06-16       Impact factor: 17.956

Review 10.  Genetic therapies against HIV.

Authors:  John J Rossi; Carl H June; Donald B Kohn
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.